SG11201408237YA - Compound as wnt signaling inhibitor, composition, and use thereof - Google Patents
Compound as wnt signaling inhibitor, composition, and use thereofInfo
- Publication number
- SG11201408237YA SG11201408237YA SG11201408237YA SG11201408237YA SG11201408237YA SG 11201408237Y A SG11201408237Y A SG 11201408237YA SG 11201408237Y A SG11201408237Y A SG 11201408237YA SG 11201408237Y A SG11201408237Y A SG 11201408237YA SG 11201408237Y A SG11201408237Y A SG 11201408237YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compound
- composition
- designated states
- guangzhou
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000011664 signaling Effects 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/077032 WO2013185353A1 (fr) | 2012-06-15 | 2012-06-15 | Composé comme inhibiteur de la voie de signalisation wnt, composition et utilisation associée |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408237YA true SG11201408237YA (en) | 2015-01-29 |
Family
ID=49757457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408237YA SG11201408237YA (en) | 2012-06-15 | 2012-06-15 | Compound as wnt signaling inhibitor, composition, and use thereof |
Country Status (16)
Country | Link |
---|---|
US (2) | US9556144B2 (fr) |
EP (1) | EP2861590B1 (fr) |
JP (1) | JP6081582B2 (fr) |
KR (1) | KR101824300B1 (fr) |
CN (2) | CN106188045B (fr) |
AU (1) | AU2012382875B2 (fr) |
BR (1) | BR112014031263B1 (fr) |
CA (1) | CA2875372C (fr) |
ES (1) | ES2649673T3 (fr) |
HK (1) | HK1209732A1 (fr) |
IL (1) | IL236242B (fr) |
IN (1) | IN2015DN00129A (fr) |
MX (1) | MX359146B (fr) |
RU (1) | RU2627712C2 (fr) |
SG (1) | SG11201408237YA (fr) |
WO (1) | WO2013185353A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2670874T3 (es) | 2011-03-16 | 2018-06-01 | Argenx Bvba | Anticuerpos contra CD70 |
JP6081582B2 (ja) | 2012-06-15 | 2017-02-15 | キュアジェニックス インコーポレイテッド | Wntシグナリング阻害剤、組成物およびその用途としての化合物 |
WO2014165232A1 (fr) | 2013-03-12 | 2014-10-09 | Curegenix, Inc. | Composés pour le traitement du cancer |
CN105120867A (zh) * | 2013-03-14 | 2015-12-02 | 广州源生医药科技有限公司 | 用于治疗纤维化疾病的化合物 |
CN105348298B (zh) * | 2014-07-04 | 2019-03-19 | 沈阳中化农药化工研发有限公司 | 取代芳基吡啶类化合物及其用途 |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
AU2016271101B2 (en) * | 2015-05-31 | 2021-04-01 | Curegenix Corporation | Combination compositions for immunotherapy |
CN107759584B (zh) * | 2016-08-16 | 2021-06-01 | 苏州云轩医药科技有限公司 | 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用 |
WO2017167150A1 (fr) * | 2016-03-31 | 2017-10-05 | 苏州云轩医药科技有限公司 | Composé hétérocyclique 3-fluoropyridine et son application |
WO2018165520A1 (fr) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Composés inhibiteurs de métalloenzymes |
KR20190136028A (ko) * | 2017-03-30 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | Hpk1 억제제로서의 나프티리딘 |
CN107510652B (zh) * | 2017-07-21 | 2018-07-13 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
CN107441045B (zh) | 2017-07-21 | 2018-10-19 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
TW202038958A (zh) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Cd70組合治療 |
WO2021224409A1 (fr) | 2020-05-06 | 2021-11-11 | Syngenta Crop Protection Ag | Dérivés hétérocycliques à action pesticide comprenant des substituants contenant du soufre |
WO2022089454A1 (fr) * | 2020-10-28 | 2022-05-05 | 杭州阿诺生物医药科技有限公司 | Composé inhibiteur de la voie wnt à haute activité |
TW202321244A (zh) * | 2021-07-26 | 2023-06-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
WO2024022365A1 (fr) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | Composé inhibiteur de la voie wnt |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8908229D0 (en) | 1989-04-12 | 1989-05-24 | Smithkline Beckman Intercredit | Compounds |
WO1993017682A1 (fr) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Antagonistes des recepteurs de l'angiotensine ii |
ATE552253T1 (de) * | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
MX2007008328A (es) * | 2005-01-07 | 2008-01-16 | Univ Emory | Antagonistas cxcr4 para el tratamiento de trastornos medicos. |
US7763731B2 (en) * | 2005-12-21 | 2010-07-27 | Abbott Laboratories | Anti-viral compounds |
US7989461B2 (en) * | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
WO2008086462A2 (fr) * | 2007-01-11 | 2008-07-17 | Wyeth | Dérivés de quinalozine substitués par amino en tant qu'inhibiteurs de la voie b-caténine/tcf-4 et agents de traitement du cancer |
NZ603789A (en) * | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
CN102558173B (zh) * | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
JP6081582B2 (ja) | 2012-06-15 | 2017-02-15 | キュアジェニックス インコーポレイテッド | Wntシグナリング阻害剤、組成物およびその用途としての化合物 |
WO2014165232A1 (fr) * | 2013-03-12 | 2014-10-09 | Curegenix, Inc. | Composés pour le traitement du cancer |
CN105120867A (zh) * | 2013-03-14 | 2015-12-02 | 广州源生医药科技有限公司 | 用于治疗纤维化疾病的化合物 |
-
2012
- 2012-06-15 JP JP2015516405A patent/JP6081582B2/ja active Active
- 2012-06-15 RU RU2014150338A patent/RU2627712C2/ru active
- 2012-06-15 KR KR1020147034377A patent/KR101824300B1/ko active IP Right Grant
- 2012-06-15 AU AU2012382875A patent/AU2012382875B2/en active Active
- 2012-06-15 BR BR112014031263-0A patent/BR112014031263B1/pt active IP Right Grant
- 2012-06-15 CN CN201610534447.6A patent/CN106188045B/zh active Active
- 2012-06-15 CN CN201280073873.4A patent/CN104379583B/zh active Active
- 2012-06-15 WO PCT/CN2012/077032 patent/WO2013185353A1/fr active Application Filing
- 2012-06-15 CA CA2875372A patent/CA2875372C/fr active Active
- 2012-06-15 MX MX2014015281A patent/MX359146B/es active IP Right Grant
- 2012-06-15 ES ES12878945.0T patent/ES2649673T3/es active Active
- 2012-06-15 SG SG11201408237YA patent/SG11201408237YA/en unknown
- 2012-06-15 US US14/408,254 patent/US9556144B2/en active Active
- 2012-06-15 EP EP12878945.0A patent/EP2861590B1/fr active Active
-
2014
- 2014-12-14 IL IL236242A patent/IL236242B/en active IP Right Grant
-
2015
- 2015-01-06 IN IN129DEN2015 patent/IN2015DN00129A/en unknown
- 2015-10-22 HK HK15110400.6A patent/HK1209732A1/xx unknown
-
2016
- 2016-11-23 US US15/359,900 patent/US10087181B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170073344A1 (en) | 2017-03-16 |
AU2012382875B2 (en) | 2017-04-20 |
US9556144B2 (en) | 2017-01-31 |
BR112014031263B1 (pt) | 2022-03-29 |
MX2014015281A (es) | 2015-06-23 |
EP2861590A1 (fr) | 2015-04-22 |
MX359146B (es) | 2018-09-17 |
CA2875372C (fr) | 2019-04-09 |
WO2013185353A1 (fr) | 2013-12-19 |
KR101824300B1 (ko) | 2018-01-31 |
CN104379583A (zh) | 2015-02-25 |
AU2012382875A1 (en) | 2014-12-18 |
NZ702413A (en) | 2016-08-26 |
IN2015DN00129A (fr) | 2015-05-29 |
CN106188045B (zh) | 2018-01-16 |
CN104379583B (zh) | 2016-06-08 |
RU2627712C2 (ru) | 2017-08-10 |
ES2649673T3 (es) | 2018-01-15 |
JP2015523348A (ja) | 2015-08-13 |
US20150119387A1 (en) | 2015-04-30 |
EP2861590B1 (fr) | 2017-10-25 |
CN106188045A (zh) | 2016-12-07 |
IL236242B (en) | 2018-04-30 |
RU2014150338A (ru) | 2016-08-10 |
HK1209732A1 (en) | 2016-04-08 |
US10087181B2 (en) | 2018-10-02 |
KR20150024826A (ko) | 2015-03-09 |
CA2875372A1 (fr) | 2013-12-19 |
BR112014031263A2 (pt) | 2018-04-24 |
EP2861590A4 (fr) | 2015-12-30 |
JP6081582B2 (ja) | 2017-02-15 |
IL236242A0 (en) | 2015-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201811184UA (en) | Lag -3 binding members | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201408821SA (en) | Selective pi3k delta inhibitors | |
SG11201408094YA (en) | Neprilysin inhibitors | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201407200TA (en) | Liquid formulation | |
SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
SG11201810519XA (en) | A rinse composition, a method for forming resist patterns and a method for making semiconductor devices | |
SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
SG11201810352XA (en) | New antibacterial compounds | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11201408119PA (en) | Systems and methods for data center cooling and water desalination | |
SG11201407987SA (en) | Catalytic surfaces and coatings for the manufacture of petrochemicals | |
SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea |